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SUMMARY
A large number of cancer drugs have been developed to target particular genes/pathways that are crucial for
cancer growth. Drugs that share a molecular target may also have some common predictive omic features,
e.g., somatic mutations or gene expression. Therefore, it is desirable to analyze these drugs as a group
to identify the associated omic features, which may provide biological insights into the underlying drug
response. Furthermore, these omic features may be robust predictors for any drug sharing the same target.
The high dimensionality and the strong correlations among the omic features are the main challenges
of this task. Motivated by this problem, we develop a new method for high-dimensional bilevel feature
selection using a group of response variables that may share a common set of predictors in addition to
their individual predictors. Simulation results show that our method has a substantially higher sensitivity
and specificity than existing methods. We apply our method to two large-scale drug sensitivity studies in
cancer cell lines. Both within-study and between-study validation demonstrate the good efficacy of our
method.
Keywords: Bilevel selection; Cancer cell lines; Drug sensitivity.
1. INTRODUCTION
Human cancer arises from an accumulation of somatic mutations during the lifetime of a patient. Inter-
ventions targeting mutated proteins or relevant pathways have proved to be effective treatment options.
However, not all the patients with the targeted somatic lesions respond to the therapy. For example, several
cancer drugs target over-expression of oncogene HER2. Among those breast cancer patients with HER2
over-expression, only 30% respond to such targeted therapy (de Palma and Hanahan, 2012). Such hetero-
geneous response may be due to underlying genomic heterogeneity, which can be manifested by different
omic features, e.g., DNA alterations, gene expression, or epigenetic marks. Preclinical model systems
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such as cancer cell lines that reflect the genomic diversity of human cancers can be used to identify pre-
dictive omic features/biomarkers for drug sensitivity (Caponigro and Sellers, 2011). Recently, two groups
(Garnett and others, 2012; Barretina and others, 2012) have studied drug sensitivity in a large number of
cancer cell lines and measured several types of omic features including somatic mutations of cancer genes,
genome-wide copy number aberrations, and gene expression. The sample size ranges from 200 to 500
per drug, while the number of omic features is greater than 10 000. The authors conducted drug-by-drug
analysis to identify associated omic features, and they demonstrated that drugs with the same targets have
some common predictive omic features in addition to their individual features. Therefore, a joint analysis
of the drugs sharing a target may improve the sensitivity and specificity to identify their shared predictive
omic features. To this end, we consider the feature selection method for multivariate responses to identify
predictive omic features of drugs with the same target.
Two types of methods have been developed for feature selection for multivariate responses: group-
wise selection and bilevel selection. Group-wise selection methods, such as group Lasso (Yuan and Lin,
2006) or group adaptive Lasso (Wang and Leng, 2008), assume that all the response variables within
a group are associated with the same set of covariates (Huang and others, 2012). This assumption is
not reasonable for cancer drug-sensitivity studies because drugs with the same target may have differ-
ent predictive omic features. In contrast, bilevel selection methods encourage the selection of covariates
associated with all the response variables, but they also allow some covariates to be associated with one
or a few response variables (Breheny and Huang, 2009). The flexibilities in bilevel selection are desirable
for cancer drug-sensitivity applications. A few methods have been developed for bilevel selection with
one or more response variables, such as group bridge (gBridge, Huang and others, 2009), composite
MCP (cMCP, Breheny and Huang, 2009), sparse-group lasso (SGL, Simon and others, 2013), group
exponential Lasso (FEb, Breheny, 2015), and group variable selection via convex log-exp-sum penalty
(Chen and others, 2014). Although these methods work satisfactorily in many real-data analyses, we
find that their performance is limited in cancer drug sensitivity studies where the response variables are
multivariate and the covariates are high-dimensional omic features with strong correlations. These issues
motivate us to develop a new method to construct predictive models of cancer drug sensitivity using omic
features.
In this article, we propose a new bilevel selection method called BipLog and apply it to analyze
the aforementioned drug sensitivity data sets. We seek to answer a few important questions in our
data analysis. First, by splitting the data from Garnett and others (2012) into training and testing
sets, we assess the variation in the drug sensitivity that can be explained by our predictive model.
Second, we use all the data from Garnett and others (2012) to select omic features associated with
each drug target, and we evaluate their prediction performance using independent data from Barretina
and others (2012). There are substantial differences in these two studies in terms of the drugs stud-
ied and the method to estimate the drug sensitivity. Therefore, this between-study comparison helps
to evaluate the robustness and generality of our method. Third, we use this between-study compari-
son to compare the results of BipLog with those of the “drug-by-drug” analysis using the elastic net
(Zou and Hastie, 2005).
The remainder of this article is organized as follows. In Section 2, we introduce of BipLog and its
implementation. We present the simulation studies and real-data analyses in Sections 3 and 4. Section 5
provides concluding remarks.
2. METHODS
2.1 Objective function
Suppose in a particular drug group that shares a target, we observe measurements of drug sensitivity of q
drugs (response variables), denoted by yk = (y1k , . . . , ynk)T (1 ≤ k ≤ q), and p omic features (covariates),
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denoted by xj = (x1j, . . . , xnj)T (1 ≤ j ≤ p) for n samples. We assume that q is much smaller than the
sample size n, but p is often larger or much larger than n. After standardizing yk and xj to have mean 0 and
‖yk‖22 = ‖xj‖22 = n, we assume a linear system: E(yk) = Xβk =
∑p
j=1 xjβjk , where Xn×p = (x1, . . . , xp)
and βk = (β1k , . . . ,βpk)T . Let β = (β1, . . . ,βq) and denote each row of β by bj = (βj1, . . . ,βjq). Let
|bj| = ∑qk=1 |βjk |. The objective function that we aim to minimize is a penalized least squares:
Q(β) = 1
2n
q∑
k=1
‖yk − Xβk‖22 +
p∑
j=1
q∑
k=1
pθ1
(|βjk |)+ p∑
j=1
pθ2(|bj|), (2.1)
where pθ1
(|βjk |) = λ1 log(|βjk | + τ1), pθ2(|bj|) = λ2 log(|bj| + τ2), θ 1 = (λ1, τ1), and θ 2 = (λ2, τ2). In
its general form, p(β) = λ log(|β| + τ) is the Log penalty for a parameter β with tuning parameters
 = (λ, τ).
In our previous works (Sun and others, 2010; Chen and others, 2015), we have shown that the Log
penalty has promising performances in genomic studies. The Log penalty was originally proposed by
Friedman (2008), and it was discussed byMazumder and others (2011) in the form of λlog(r+1) log(r|β|+1),
with r > 0 and λ > 0. By applying L’H™ôpital’s rule to this form of Log penalty, it can be shown that
it bridges the L1 penalty (as r → 0+) and the L0 penalty (as r → ∞). The Log penalty in (2.1) is
a reparameterization of this form. The Log penalty is a nonconvex penalty or more precisely a folded
concave penalty (Fan and Lv, 2010) in the sense that it is concave for β ∈ [0,∞), with continuous
derivative p′(β) ≥ 0, and p′(0+) > 0. Similar to other types of folded concave penalties, the Log
penalty mitigates the estimation bias produced by convex penalty (e.g., Lasso penalty) and it can achieve
variable selection consistency without requiring restricted irrepresentable condition (Zhao andYu, 2006).
We achieved bilevel selection by applying Log penalties to each coefficient (
∑p
j=1
∑q
k=1 pθ1
(|βjk |)) and
each group of coefficients (
∑p
j=1 pθ2(|bj|)), respectively. In the following section, we will give more
explanation and justification of this particular form of bilevel penalty.
2.2 Computation
We estimate the β that minimizes Q(β) in (2.1) using a combination of local linear approximation (LLA)
(Zou and Li, 2008) and a coordinate descent algorithm. Specifically, given initial values of β or the
estimates from the tth iteration, denoted {βˆ(t)jk }, we apply LLA to the Log penalty functions pθ1
(|βjk |) and
pθ2
(|bj∣∣) to update them at the (t + 1)th iteration:
pθ1
(|βjk |) ≈ pθ1 (|βˆ(t)jk |)+ ∂pθ1
(|βjk |)
∂|βjk |
∣∣∣∣∣
|βjk |=|βˆ(t)jk |
(
|βjk | − |βˆ(t)jk |
)
= λ1|βjk ||βˆ(t)jk | + τ1
+ C1,
pθ2(|bj|) ≈ pθ2
(
|bˆ(t)j |
)
+
q∑
k=1
∂pθ2
(|bj|)
∂|βjk |
∣∣∣∣∣
|βjk |=|βˆ(t)jk |
(
|βjk | − |βˆ(t)jk |
)
=
q∑
k=1
λ2|βjk |
|bˆ(t)j | + τ2
+ C2,
where C1 and C2 are constants with respect to βjk . Then the objective function at the (t + 1)th iter-
ation, denoted Q˜(t+1)(β), can be written Q˜(t+1)(β) = 12n
∑q
k=1 ‖yk − Xβk‖22 +
∑p
j=1
∑q
k=1
λ1|βjk |
|βˆ(t)jk |+τ1
+∑p
j=1
∑q
k=1
λ2|βjk |
|bˆ(t)j |+τ2
. We use a coordinate descent approach to find each regression coefficient βjk
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sequentially. Let β¯(t)jk = (1/n)
∑n
i=1 xij
(
yik −∑l =j xilβˆ(t)lk ), to solve for βjk , we minimize
Q˜(βjk) = 12
(
βjk − β¯(t)jk
)2 +
{
λ1
|βˆ(t)jk | + τ1
+ λ2∑q
k=1 |βˆ(t)jk | + τ2
}
|βjk |. (2.2)
This “LLA + coordinate descent” algorithm alternates through different iterations indexed by t, and within
each iteration, it estimates all the regression coefficients sequentially. Finally, this algorithm is considered
to have converged if the maximum difference in the coefficient estimates between consecutive iterations
is less than a predefined threshold, say 10−4.
The penalty term in (2.2) can be written as an adaptive Lasso (Zou, 2006) form of λ1wˆjk |βjk | with
wˆjk =
[(
|βˆ(t)jk | + τ1
)−1 + λ2
λ1
(∑q
k=1 |βˆ(t)jk | + τ2
)−1]
. In contrast to the adaptive Lasso, which adapts a
weight function 1/|βˆ(t)jk |, our weight function is a weighted sum of the contributions of the individual
coefficient estimates (|βˆ(t)jk |+ τ1)−1 and the group-level estimates (
∑q
k=1 |βˆ(t)jk |+ τ2)−1, with weights 1 and
λ2/λ1, respectively. Note that the inclusion of tuning parameters τ1 and τ2 prevents an infinite penalty
for any regression coefficient with a previous estimate of 0. This is necessary for the iterative estimation
procedure to proceed with one or more regression coefficients penalized to 0.
Next we show that an alternative group penalty using an L2 norm (i.e., λ2 log
(‖bj‖2 + τ2)) is not
appropriate. With the L2 norm in group penalty, the intermediate objective function in (2.2) becomes
Q˜(t+1)(βjk) = 12
(
βjk − β¯(t)jk
)2 + λ1|βjk ||βˆ(t)jk |+τ1 +
λ2|βˆ(t)jk ||βjk |
‖bˆ(t)j ‖22+τ2‖bˆ
(t)
j ‖2
. It is easy to show that this group-level penalty
does not deliver the desirable property when ‖bˆ(t)j ‖2 > 0. Specifically, a nonzero coefficient βjk may be
penalized to zero in the tth iteration, and the group-level penalty may “rescue” it by borrowing information
across βjk ′ ’s for k ′ = k . However, using this L2 norm group penalty, the penalty for βjk equals to 0 as long
as βˆ(t)jk = 0, and thus it cannot borrow information across βjk ′ ’s.
Finally, we will discuss the role of the individual-level penalty pθ1
(|βjk |) in our method. If we remove
this penalty term, the intermediate objective function of coordinate descent algorithm shown in (2.2)
becomes Q˜(βjk) = 12
(
βjk − β¯(t)jk
)2 +{ λ2∑q
k=1 |βˆ
(t)
jk |+τ2
}
|βjk |.A bilevel variable selection can still be achieved
because the group information contributes to the weight term and the term |βjk | in the penalty function
delivers individual penalty. In fact, Huang and others (2012) has pointed out that applying a folded con-
cave penalty to the L1 norm of a group of coefficients achieves bilevel selection. However, in our method,
by including pθ1
(|βjk |) in the overall objective function, the individual coefficient estimate can also
contribute to the weight and thus provide more information for penalized estimation. The following sim-
ulation study shows that the performance of BipLog becomes worse without the individual-level penalty
pθ1
(|βjk |).
2.3 A Bayesian interpretation of BipLog
The following Bayesian interpretation provides additional insight into our method and the role of the tun-
ing parameters. Recall that bj = (βj1, . . . ,βjq)T are the regression coefficients for the jth covariate across
the q response variables. Our BipLog penalty can be derived from a Bayesian setup using the follow-
ing priors: p(bj|ωj1, . . . ,ωjq,ωj) =
{∏q
k=1
1
2 (ω
−1
jk + ω−1j ) exp
(
−|βjk |
ωjk
)}
exp
(
−
∑q
k=1 |βjk |
ωj
)
; p(ωjk |δ1, τ1) =
inv-Gamma(ωjk ; δ1, τ1); p(ωj|δ2, τ2) = inv-Gamma(ωj; δ2, τ2), where δ1 > 0, δ2 > 0, τ1 > 0, and τ2 > 0
are four hyperparameters. Given the above specification, after integrating out ωjk and ωj, we obtain the
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density ofbj: f (bj|δ1, τ1, δ2, τ2) ∝ τ
δ2
2 δ2
2(
∑q
k=1 |βjk |+τ2)1+δ2
∏q
k=1
τ
δ1
1 δ1
2(|βjk |+τ1)1+δ1
, and− log{f (bj|δ1, τ1, δ2, τ2)} gives
exactly the same form of the BipLog penalty as in (2.1) if we set nλ1 = 1+ δ1 and nλ2 = 1+ δ2. This also
gives more insight into the scale of the tuning parameters of λ1 and λ2. Empirically, the grids of possible
values of λ1 and λ2 could be set at the scale of n−1 since both δ1 and δ2 are constant O(1).
2.4 Tuning parameter selection
We choose the best set of tuning parameters by a grid search over an initial pool of tuning values. On the
basis of the Bayesian interpretation of BipLog, we set λ1 = (1 + δ1)/n and λ2 = (1 + δ2)/n. The initial
values for δ1 and δ2 range from 0 to 5.0with a 0.5 increment. The initial values for τ1 and τ2 are from 10−3 to
two times of maxj,k{|βˆmlsjk |} and two times of maxj{
∑q
k=1 |βˆmlsjk |}, respectively, where βˆmlsjk denotes marginal
regression coefficient estimate for the kth response and the jth covariate. The rationale of this choice is
similar for both τ1 and τ2. Use τ1 as an example. If τ1 is too small compared to the smallest nonzero value
of |βjk |, pθ1 is mainly depend on |βjk |. If τ1 is too large, the effect of |βjk | on the penalty becomes negligible.
We use the marginal regression coefficients as data-driven quantities to generate the approximate range of
τ1 and τ2. Our simulation studies show that this solution works well in practice. We select a combination
of tuning parameters using the extended BIC (Chen and Chen, 2008). The extended BIC for a model m
is BIC	(m) = −2 log ln{θˆ(m)} + κm log n+ 2	 log ς(Sκm), where ln{θˆ(m)} is the log likelihood, θˆ(m) are
the estimates of all the parameters, κm is the degree of freedom for model m, and ς(Sκm) is the number
of models with degree of freedom equal to κm. Specifically, ln{θˆ(m)} is calculated using the penalized
coefficient estimates assuming a multivariate Gaussian distribution.We set κm to be the number of nonzero
coefficients and ς(Sκm) =
(pq
κm
)
, i.e., the number of choices of κm coefficients from a total of pq regression
coefficients. In addition, following Chen and Chen (2008), we set 	 ≈ 1 − 1/[2log(pq)/log n].
3. SIMULATION STUDIES
3.1 Simulation setup
It is difficult to simulate high-dimensional genomic data with a realistic correlation structure except in
a few special cases, for example, genetic data from experimental cross. We create the simulation setting
as in Sun and others (2010). Using the function sim.map in R/qtl (Broman and others, 2003), we first
simulated a genetic marker map of 2000 single-nucleotide polyneorphines (SNPs) from 20 chromosomes
of length 90 cM, with 100 SNPs per chromosome. Then we used the function sim.cross in R/qtl to
simulate the genotype data of an F2 cross with sample size n = 200 based on the simulated marker map.
As expected, the simulated genotypes show strong correlations for nearby SNPs (average R2 is 0.96 for
SNPs within 1 cM) and negligible correlation for SNPs from different chromosomes. The following real
data analysis will consider the data sets including p to be more than 13000 and about 500 samples. To
save the computation time, we randomly selected p = 600 SNPs from the 2000 SNPs for the following
simulation of quantitative traits.
We simulated a total of q = 30 quantitative traits from themultivariate linearmodelYn×q = Xn×pβp×q+
En×q, where Y = (y1, . . . , yq). The residuals E were simulated from a multivariate Gaussian distribution
with mean 0 and compound symmetry covariance structure with diagonal variance (0.25 + 0.5) and off-
diagonal covariance 0.5. Traits 1–10 share a pair of causal SNPs, and each has its own causal SNP. Traits
11–30 do not have individual causal SNPs. Traits 11–20 share two pairs of causal SNPs, and traits 21–30
share one pair of causal SNPs. The pairs of causal SNPs shared across traits may be located in different
chromosomes (unlinked) or at the same chromosome with the effect sizes being (η, η) (SNPs linked in
coupling) or (η,−η) (SNPs linked in repulsion). We consider two effect sizes η = 0.3 or 0.6. Given the
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Fig. 1. Comparisons of six bilevel selection methods (SGL, gBridge, cMCP, gel), BipLog-p2only and BipLog) via
simulation studies. For each of the 3 simulation scenarios with effect size η = 0.6, 30 traits are considered. The
total number of true trait-SNP associations is 90, which includes 10 associations due to SNPs affecting only one trait
(individual SNPs) and 80 associations due to SNP pairs shared across traits (shared SNPs).
three relationships between the causal SNP pairs and the two effect sizes, there are six simulation scenarios
in total.
We compared BipLog with five other approaches: SGL (Simon and others, 2013), gel (Breheny,
2015), gBridge, cMCP (Huang and others, 2012), and BipLog with only group penalty pθ2 . We used
the implementation of gel, gbridge and cMCP in R/grpreg, with the default choice of 1000 tuning values
for the tuning parameter λ, which were uniformly distributed on a log scale. In addition, we used the
implementation of SGL in R/SGL with the default choice of 20 values of the tuning parameter. Because
the R package R/SGL can only take univariate instead of multivariate response variable, we collapse Yn×q
into a vector of length nq: y˜ = (yT1 , . . . , yTq )T and generate a new covariate data matrix of dimension
nq × pq by creating a block diagonal matrix X˜ = diag{X, . . . ,X} with q identical matrix Xn×p. This
approach allows us to analyze multivariate data by a univariate regression of y˜ vs. X˜, but it increases the
dimensionality of the covariate matrix and hence the computation time. Using the default number of 20
values of tuning parameter generated by the R package R/SGL takes about 5 h to finish one simulation,
and thus we did not increase the number of tuning values. Similar transformation of data is needed to
apply group variable selection via convex log-exp-sum penalty (Chen and others, 2014), which takes
much longer computational time, and thus we did not evaluate the results of this approach.
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We compare the performance of these methods across the range of tuning parameters by ROC-like
curves. Specifically, instead of comparing true-positive rate (i.e., sensitivity) vs. false-positive rate (i.e.,
1 - specificity) in regular ROC curves, we compare true-positive rate vs. false discovery rate (FDR). In
high-dimensional settings, FDR is a more appropriate measure of accuracy than specificity. Let s be the
number of causal SNPs, and let D be the number of discoveries, i.e., the number of nonzero regression
coefficient estimates. D = TD+FD, where TD and FD are the number of true and false discoveries. Then
FDR = FD/D and true-positive rate = TD/s. In addition, we also considered the average estimation bias
of nonzero effect sizes as the average of |βˆjk − βjk |/|βjk | × 100% for any βjk = 0, where βjk ’s are the
true effect sizes. Small bias is crucial for the success of tuning parameter selection using either BIC or
cross-validation because both criterion rely on model fit, which in turn relies on unbiased estimates of
effect sizes. We considered a 10% interval for the FDR from 0% to 100% and for all the models within
the same FDR interval, we select the highest true-positive rate and the lowest estimation bias.
Figure 1 shows the median of those measurements across 100 simulations for each of the methods to be
compared: BipLog, BipLog-p2only (BipLog with only group penalty pθ2 ), gBridge, cMCP, gel, and SGL
when η = 0.6. In the “coupling” and “independent” setting, BipLog and cMCP have best performance in
terms of FDR and sensitivity, and the estimates from BipLog have smaller bias than those from cMCP. In
the “repulsion” setting, BipLog has much better performance than cMCP in terms of variable selection or
bias. gBridge also has good performance (though slightly worse than BipLog) in all three settings. BipLog
with only group penalty (BipLog_p2only) has poor performance in all the three settings. The results for
η = 0.3 reach similar conclusions except that cMCP shows worse performance in the independent setting
and gBridge shows better performance in the repulsion setting (see Figure 1 of supplementary material
available at Biostatistics online).
4. OMIC SIGNATURES OF CANCER DRUG SENSITIVITY
To identify the omic features associated with the cancer drugs’ sensitivity, both Garnett and others (2012)
and Barretina and others (2012) generated omic and pharmacological data for a panel of human cancer
cell lines, which represent the characteristics of various types of cancers. Garnett and others (2012)
measured the mutation statuses of 64 commonly mutated cancer genes (exon sequencing), genome-
wide copy number alterations (Affymetrix SNP array 6.0), and gene expression (Affymetrix HT-U133A
microarray), while Barretina and others (2012) measured the mutation statuses of 1600 genes (targeted
sequencing), genome-wide copy number alterations (Affymetrix SNP array 6.0), and gene expression
(Affymetrix U133 plus 2.0 array). In the study of Garnett and others (2012), 130 drugs were screened for
drug sensitivity analysis in a range of 275–507 cell lines from a panel of 639 human tumor cell lines. In the
study of Barretina and others (2012), 24 drugs were screened for drug sensitivity analysis for 500 cell lines
on average from a panel of 947 human tumor cell lines. In both studies, the drug sensitivity was assessed
by IC50, which is half-maximal inhibitory concentration.All the data used in this section were downloaded
from http://www.broadinstitute.org/ccle/data/browseData and http://www.cancerrxgene.org/downloads/.
4.1 Evaluation of prediction model in the study of Garnett and others (2012) by cross-validation
Of the 130 drugs analyzed by Garnett and others (2012), 41 have nonmissing IC50 values in fewer
than 331 cell lines, while the other 89 drugs have nonmissing IC50 values in more than 461 cell lines.
These 89 drugs were grouped by their targets, and two drugs were excluded from our analysis because
they do not group with any other drugs. We will first study these 87 drugs since a larger sample size is
necessary for the following analyses using training/testing sets. Of the 87 drugs, 57, 69, and 56 are grouped
by targeted family, targeted process, and targeted molecule, respectively. The three grouping strategies
have a semihierarchical order: targeted family > targeted process > targeted molecule. One drug is
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often grouped in multiple ways. There are four targeted families: chemotherapy, cytoplasmic/nonreceptor
tyrosine kinase (CTK), receptor tyrosine kinase (RTK), and serine/threonine protein kinase (S/T Kinase),
which include 12, 7, 10, and 30 drugs, respectively. There are 18 targeted processes (typically with
less than 10 drugs per process) and 24 targeted molecules groups (typically with less than 10 drugs
per molecule).
We randomly selected 65 cell lines from those with nonmissing IC50 values for all 87 drugs as testing set
and used the remaining cell lines as the training set. The training set was used for feature selection, and the
tuning parameter was selected by the extended BIC. If a drug belonged tomore than one group, we took the
union of the omic features associated with that drug across the groups. To obtain the regression coefficients
estimates for the union of the omic features associated with each drug, we re-estimated the regression
coefficients for each drug separately using the training data (denoted βˆ train) by linear regression. Thus a
predictive model for each drug was obtained. Next, we used the testing data to estimate the percentage
of the variance explained by the predictive model. Let SSz be the sum of squares of z, and let ytest and
Xtest be the standardized log(IC50) and omic features in the testing set. Then Prediction R-square ≡
1 − SStestSSytest , where  test = ytest − Xtestβˆ train. The possible range for prediction R-square is (−∞, 1]. To
evaluate the significance of prediction R-square for a drug with k associated features, we randomly
chose k features from the candidate 13 847 omic features to estimate prediction R-square and repeated
it for 1000 times to generate a null distribution. Then we calculated a p value as the percentage of the
null prediction R-squares ≥ the observed one. It took 8 s on average to generate the p value for each
drug.
BipLog identified that 70 of the 87 drugs were associated with at least one omic feature (Figures 2(a)
and (b)). Forty-nine drugs had prediction R-squares greater than 0, and 17 had values greater than 20%.
Forty-one of the drugs had significant prediction R-squares at the 0.05 significance level (Figure 2c),
which corresponds to an estimate of FDR = 87 × 0.05/41 ≈ 0.1. Overall, these results suggest that the
identified omic features could provide useful predictions of drug sensitivity.
4.2 Construction of prediction model using all the data from Garnett and others (2012)
Next, we combined the training and testing sets and selected the omic features using all the available data
for the 87 drugs. A few examples were shown in Figure 3, and the complete results can be found in the
Supplementary materials available at Biostatistics online. The abnormal gene BCR-ABL is formed by
the fusion of genes BCR and ABL, and it is often observed in chronic myeloid leukemia (CML). BCR-
ABL encodes a tyrosine kinase that is not regulated by cellular signals and thus causes unregulated cell
proliferation, which may lead to cancer. Three drugs that target BCR-ABL protein products are included
in this study (Figure 3A). The sensitivity of two of these drugs is negatively correlated with the occurrence
of the BCR-ABL mutation, which is expected. The negative correlation indicates that the presence of
the BCR-ABL mutation is related to a reduction in log(IC50), hence an increase in the drug sensitivity.
There are two interesting new findings in this example. (i) The sensitivity of AP-24534 also increases as
the expression of AZU1 increases, which is consistent with the tumor suppressor role of AZU1. (ii) The
sensitivity of Bosutinib is associated with the expression of two cancer-related genes, EGFR and CAV2,
instead of the BCR-ABL mutation. EGFR is a signaling protein that plays an important role in many types
of cancer, and CAV2 is potentially a tumor suppressor (Lee and others, 2011).
Figure 3B shows that when the gene encoding PHLDA1 has a higher expression, all four drugs that
target MEK1/MEK2 have higher sensitivity. Several previous studies have suggested that PHLDA1 may
be functionally important in cancer, and some studies have shown that it functions in the MEK1/MEK2
pathway (Oberst and others, 2008). This finding suggests that the expression of PHLDA1 could be an
informative biomarker for the efficacy of cancer drugs targeting MEK1/MEK2.
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Fig. 2. Summary of the genomic feature selection results of the within-study analysis. (a) Distribution of the number
of omic features selected per drug. (b) Distribution of the prediction R-squares for each drug. (c) Distribution of the
p values of the prediction R-squares. (d) Scatter plot of the prediction R-squares and their corresponding p values.
Since the null distribution was simulated as 1000 null samples, the smallest p value is 0.001.
The ERBB2 gene encodes a protein product that promotes the growth of cancer cells. Our anal-
ysis identifies several genes related to the two drugs targeting ERBB2 (Figure 3C): BIBW2992 and
Lapatinib. BIBW2992 has been approved for use against nonsmall cell lung carcinoma, and its effi-
cacy for breast cancer treatment is being evaluated. Lapatinib has been approved for treatment in
advanced ERBB2-receptor-positive breast cancer patients. As expected, we identified the ERBB2 muta-
tion or the copy number variation as omic features associated with these drugs. The novel findings
are the association with the gene expressions of C1ORF116, CYR61, and STAM2. C1ORF116 inter-
acts with SMD2, which is closely related to tumorigenesis. Several studies have shown that CYR61
is involved with breast cancer tumorigenesis and progression. In addition, STAM2 may be involved in
“signaling by EGFR in cancer" (Croft and others, 2011). Therefore, the combined information from
the ERBB2 mutation (or copy number alterations) and gene expression of C1ORF116, CYR61, and
STAM2 may provide a more accurate prediction of drug efficacy than the ERBB2 mutation/copy number
alteration alone.
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B. MEK1/MEK2
D. Mitosis
Vinorelbine EpothiloneB Vinblastine Docetaxel BX-795 SL0101-1 BI-D1870 ZM-447439 RO-3306
ABCB1 0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
YAP1 0.00 0.00 –0.25 –0.24 0.00 0.00 –0.10 0.00 0.00
AXL 0.00 –0.13 0.00 –0.17 –0.36 0.00 0.00 –0.19 –0.15
blood 0.00 0.00 0.00 0.28 0.18 0.00 0.33 0.21 0.15
RDEA119 CI-1040 PD-0325901 AZD6244
PHLDA1 –0.49 –0.39 –0.43 –0.36
A. BCR_ABL AP-24534 Nilotinib Bosutinib
EGFR 0.00 0.00 –0.19
AZU1 –0.20 0.00 0.00
CAV2 0.00 0.00 –0.19
BCR_ABL_MUT –0.39 –0.67 0.00
C. ERBB2
Lapatinib BIBW2992
C1ORF116 –0.31 –0.36
CYR61 –0.35 0.00
ERBB2_CN 0.00 –0.26
ERBB2_MUT –0.31 0.00
STAM2 0.00 –0.16
Fig. 3. Omic features associated with four groups of drugs that share the molecular targets BCR_ABL (A),
MEK1/MEK2 (B), ERBB2 (C), or the process target Mitosis (D). For each group, the regression coefficient matrix
is shown for those omic features with at least one nonzero coefficient, where a row corresponds to a genomic feature
and a column corresponds to a drug. The feature X_MUT is a binary indicator showing whether gene X has mutation;
ERBB2_CN is the copy number of the gene ERBB2; blood is a binary indicator showing whether the cell line is
derived from a blood tumor. The remaining features are gene expressions.
Figure 3D presents the estimated coefficient matrix for nine drugs that target the Mitosis process.
The features shared by several drugs include the expression of genesYAP1 andAXL and the blood-tissue
indicator.YAP1 encodes “YES-associated protein 1,” which has been shown to be related to different types
of cancer. AXL encodes a receptor tyrosine kinase, which is also involved with tumorigenesis. Previous
studies have shown that the protein products of YAP1 and AXL may function together (Cui and others,
2011).
4.3 Validation of the prediction model on the data from Barretina and others (2012)
We treated the data of Garnett and others (2012) and Barretina and others (2012) as the training and testing
study data, respectively. Of the 24 drugs analyzed by Barretina and others (2012), 12 were analyzed in
the training study. Five of the 12 drugs had missing values in more than 325 cell lines in the training
study, so they were not included in the 87 drugs in the above analysis. To address this issue, we conducted
another group-wise analysis using the training data for groups involving any of these 12 drugs. Then we
chose the features associated with each drug as the union of the features selected in this new analysis and
those from the above analysis, whenever possible. For the 12 drugs that were analyzed using the testing
data but not the training data, we fitted the prediction models using the features selected for their drug
targets. For example, for the drug Topotecan, which targets the molecule TOP1, we used the features
from the training study associated with the drug group that targeted TOP1 as the features associated with
Topotecan.
To determine whether at least one of the selected features is associated with drug sensitivity in the
testing data, we used an F test to compare the intercept-only model and the model with all the identified
omic features (Figure 4). The p values are smaller than 0.05 in most cases. The drugs PLX4720 and
Lapatinib are particularly significant, with p values of 10−39 and 10−17, respectively.
To compare the omic features identified by our method and the elastic net in the study of Garnett and
others (2012), we calculated the prediction R-square of log(IC50) in the testing study for the 12 drugs
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Fig. 4. Evaluation of the predictive model in the study of Barretina and others (2012); the models themselves were
constructed using the data of Garnett and others (2012). The “validated drugs” are the drugs that were analyzed in
both studies. The inferred drugs are the drugs that were analyzed only in the study of Barretina and others (2012). The
x-axis shows the drug targets, and the y-axis shows the − log 10(p values) from the F test that compares the model
with all the identified omic features to the intercept-only model using the data of Barretina and others (2012). The
numbers in brackets are the number of features in the corresponding prediction model.
Table 1. Prediction R-squares in the study of Barretina and others (2012).
Drug 17-AAG AZD6244 PD-0325901 PLX4720 Erlotinib Lapatinib
Groupwise analysis by BipLog
Prediction R2 [Num of X] 15% [5] 2.5% [1] 7.3% [1] 27% [3] < 0.0% [2] 21% [5]
p value < 0.001 < 0.001 < 0.001 < 0.001 1.00 < 0.001
Drug-by-drug analysis by elastic net
Prediction R2 [Num of X] 15% [16] 10% [7] 29% [17] 29% [5] 1.5% [7] 14% [16]
p value < 0.001 0.275 < 0.001 0.525 0.949 0.430
analyzed in both the training and testing studies. Because of the disparate ranges and scales of log(IC50)
in the two studies, as shown in Figure 5 of supplementary material available at Biostatistics online, we
could not directly use the regression coefficients estimated from training study. Instead, for each drug, we
randomly split the cell lines in the testing data into two groups of equal size as set 1 and set 2. We used
set 1 to estimate the linear regression coefficients of the features identified by the training data. Then we
used set 2 to estimate the prediction R-square. We repeated this procedure 100 times to obtain median
prediction R-squares as our final estimates. Then we applied Monte Carlo simulations to evaluate the
significance of the prediction R-squares, similar to our approach in Section 4.1.
Of the 12 drugs, six had a prediction R-square greater than 0 using a set of features selected by our
method or the elastic net analysis in the training study. The results for these six drugs are presented in
Table 1. In general, BipLog tended to choose more parsimonious models than those chosen by the elastic
net, and the estimates of the prediction R-square were statistically significant in all but one case. Some of
the models selected by the elastic net had greater prediction R-squares than those from BipLog. However,
because more variables were included in the model, they were not significantly larger than what was
expected from the null distributions.
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5. CONCLUSION AND DISCUSSION
We have presented a new method, BipLog, for the bilevel selection of omic features related to cancer
drug sensitivity. BipLog can select the covariates shared by a group of response variables as well as the
covariates that are associated with one or a few of the response variables. The application of BipLog to
real-data analysis reveals many interesting results. This is partly due to the strong effect size in the data.
In contrast to genome-wide association studies where a genetic variant may explain only a few percentage
of the variation in the trait of interest, the omic features measured in tumor tissues have a strong influence
on the cancer progression and its response to drug treatment.
We have implemented ourmethod in an R packagewith C code for computationally intensive part of the
computation. Although using four tuning parameters does incur higher computational load, our method
is computationally feasible for the problems we aim to solve. For example, in the simulation setting with
n = 200, p = 562, q = 30, and with a total 6000 combinations of the four tuning parameters, it takes
about 30 min to finish the computation. Considering an example in our real application, it takes about 1 h
to finish computation for a data set with n = 462, p = 13, 062, and q = 8.We have also evaluated how the
values of the four tuning parameters influence the performances of BipLog using the same data set used in
our simulation studies with η = 0.6 (See Figures 2–4 of supplementary material available at Biostatistics
online). Our results suggest the performance of our method does not change much with respect to the
choice of δ1 and δ2 (note that λ1 = (1 + δ1)/n and λ2 = (1 + δ2)/n), and thus it is possible to set them as
fixed values such as 3.5 or 4.0.
SUPPLEMENTARY MATERIAL
Supplementary material is available at http://biostatistics.oxfordjournals.org.
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